High-risk prostate cancer treatment before and after surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older.
- You have been diagnosed with prostate cancer that is considered high-risk or unfavorable intermediate-risk based on your Gleason score (7 or higher, with a pattern of 4+3).
- Your cancer has certain genetic markers (Decipher score above 0.45 or Luminal B subtype) found on your biopsy.
- You have not had chemotherapy or radiation for prostate cancer before.
- You have not had prior treatment with certain prostate cancer drugs (like enzalutamide, abiraterone, or Darolutamide itself) or with immunotherapy drugs (like PD-1/PD-L1 inhibitors).
- You are in generally good health (able to care for yourself and perform daily activities) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.